Emerging Biopharma: Your Next 2 Geographic Markets To Tackle After The US
By Paul Brennan, CEO, NervGen Pharma Corp.
While the majority of the world’s drug development and innovation are underwritten by the United States, emerging drug developers should not overlook two major regions of the world that represent volume, profit, ingenuity, and growth. U.S. pharma R&D has grown from $2 billion in 1980 to over $64.3 billion by 2019 according to PhRMA, but drug and biologics developers should not overlook the key regions of Europe and Japan when building a growth plan.
US Pricing Pays For Global Innovation
The pricing and reimbursement system in the U.S. pays for innovation and it results in pharmaceutical piggybacking in the rest of world. If it works in the U.S., you know it can work anywhere. Unlike other countries, the U.S. does not authorize drug price regulation to control pharmaceutical spending, so as not to depress the flow of capital to support the development of new pharm
Emerging Biopharma Your Next 2 Geographic Markets To Tackle After The US
pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
Chronic Obstructive Pulmonary Disease Drugs Market To Rise in the 7MM By 2030, Analysis by DelveInsight
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Indiana s Life Science Sector Drives State s Economic Health - Inside INdiana Business
insideindianabusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insideindianabusiness.com Daily Mail and Mail on Sunday newspapers.